Linked Life Data

17929018

Source:http://linkedlifedata.com/resource/pubmed/id/17929018

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2008-3-19
pubmed:abstractText
As antifungal agents are frequently used in hematology and oncology, economic data on the empirical therapy of suspected systemic fungal infection are pivotal. Data were analyzed according to: (1) the rate of nephrotoxicity related to treatment with caspofungin in comparison to liposomal amphotericin B (L-AmB) from a randomized clinical trial, (2) the effect of nephrotoxicity on length of hospital stay from a European observational study, and (3) an example of total bottom-up cost in a department of hematology in Germany. All estimates include 95% confidence intervals (CI) using two-stage Monte Carlo simulation on binominal and Gaussian random variables from separate studies with comparable populations. Overall, 8.9 (95% CI 5.9-12.1) fewer patients (of 100 randomized) experienced worsening of renal function with caspofungin vs L-AmB, giving a number needed to treat for one patient to be harmed by L-AmB of 12 (95% CI 8-17). This was estimated to translate into 5.3 extra days in hospital (95% CI 1.6-9.1) per event or 0.48 days (95% CI 0.14-0.88) worth 298 euro (95% CI 89-554) per patient receiving L-AmB rather than caspofungin. From the hospital perspective, use of caspofungin was estimated to be cost-neutral compared to L-AmB at a per diem total hospital cost of 428 euro with, and 1284 euro without, consideration of supplementary reimbursement (Zusatzentgelt) of both L-AmB and caspofungin. The data presented in this scenario show that use of caspofungin in hematology-oncology departments in Germany results in shorter hospital stays and is at least cost-neutral compared to use of L-AmB.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/17929018-10072411, http://linkedlifedata.com/resource/pubmed/commentcorrection/17929018-10585786, http://linkedlifedata.com/resource/pubmed/commentcorrection/17929018-11306148, http://linkedlifedata.com/resource/pubmed/commentcorrection/17929018-11429479, http://linkedlifedata.com/resource/pubmed/commentcorrection/17929018-11803351, http://linkedlifedata.com/resource/pubmed/commentcorrection/17929018-12069910, http://linkedlifedata.com/resource/pubmed/commentcorrection/17929018-12471588, http://linkedlifedata.com/resource/pubmed/commentcorrection/17929018-13680169, http://linkedlifedata.com/resource/pubmed/commentcorrection/17929018-15044925, http://linkedlifedata.com/resource/pubmed/commentcorrection/17929018-15309496, http://linkedlifedata.com/resource/pubmed/commentcorrection/17929018-15459300, http://linkedlifedata.com/resource/pubmed/commentcorrection/17929018-15616906, http://linkedlifedata.com/resource/pubmed/commentcorrection/17929018-15880133, http://linkedlifedata.com/resource/pubmed/commentcorrection/17929018-16838223, http://linkedlifedata.com/resource/pubmed/commentcorrection/17929018-17353573, http://linkedlifedata.com/resource/pubmed/commentcorrection/17929018-17419744, http://linkedlifedata.com/resource/pubmed/commentcorrection/17929018-3374545, http://linkedlifedata.com/resource/pubmed/commentcorrection/17929018-8842991
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0939-5555
pubmed:author
pubmed:issnType
Print
pubmed:volume
87
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
311-9
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital setting.
pubmed:affiliation
Outcomes Research, MSD Sharp and Dohme GmbH, Haar, Germany. peter_kaskel@msd.de
pubmed:publicationType
Journal Article, Randomized Controlled Trial